APLS 8-K 2026-01-12

Apellis Pharmaceuticals, Inc. (APLS) 8-K dated 2026-01-12 — accession 0001193125-26-010540. This URL is the filing, not the APLS hub.

Apellis Pharmaceuticals, Inc. (APLS) is a biotechnology company listed on US.

Apellis Pharmaceuticals, Inc. filed a 8-K on 2026-01-12. Accession 0001193125-26-010540.

Cached items: 2.02, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported APLS revenue for 2025-12-31 was $1.00B. Net income was $22.4M. Revenue was up 28.5% from 2024-12-31 to 2025-12-31. APLS currently screens at market cap $2.29B.

Not investment advice. The APLS SEC hub lists recent forms. The stock page is the research view.